| Ethel D Weld, MD | |
|
22 S Greene St, Baltimore, MD 21201-1544 | |
| (410) 328-2882 | |
| (410) 328-7607 |
| Full Name | Ethel D Weld |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 18 Years |
| Location | 22 S Greene St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497879340 | NPI | - | NPPES |
| 510435100 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | D71039 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 4981745098 | 571 |
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
The Centers for Disease Control and Prevention on Monday awarded $10 million to five medical centers to develop and test new approaches to combating infections acquired in hospitals and other care settings.
While more American mothers are breastfeeding today, non-Hispanic Black/African American women are less likely to initiate and continue breastfeeding, primarily due to a lack of desire and lack of self-efficacy, according to research presented Monday, Oct. 4, at the American Academy of Pediatrics (AAP) National Conference and Exhibition in San Francisco.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
Researchers at the Intermountain Medical Center Heart Institute in Salt Lake City have identified a biological process that may help physicians predict when someone with heart disease is likely to have a heart attack in the near future.
› Verified 4 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
The Centers for Disease Control and Prevention on Monday awarded $10 million to five medical centers to develop and test new approaches to combating infections acquired in hospitals and other care settings.
While more American mothers are breastfeeding today, non-Hispanic Black/African American women are less likely to initiate and continue breastfeeding, primarily due to a lack of desire and lack of self-efficacy, according to research presented Monday, Oct. 4, at the American Academy of Pediatrics (AAP) National Conference and Exhibition in San Francisco.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
Researchers at the Intermountain Medical Center Heart Institute in Salt Lake City have identified a biological process that may help physicians predict when someone with heart disease is likely to have a heart attack in the near future.
› Verified 4 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1902332133 PECOS PAC ID: 4981745098 Enrollment ID: O20170818000085 |
News Archive
The Centers for Disease Control and Prevention on Monday awarded $10 million to five medical centers to develop and test new approaches to combating infections acquired in hospitals and other care settings.
While more American mothers are breastfeeding today, non-Hispanic Black/African American women are less likely to initiate and continue breastfeeding, primarily due to a lack of desire and lack of self-efficacy, according to research presented Monday, Oct. 4, at the American Academy of Pediatrics (AAP) National Conference and Exhibition in San Francisco.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
Researchers at the Intermountain Medical Center Heart Institute in Salt Lake City have identified a biological process that may help physicians predict when someone with heart disease is likely to have a heart attack in the near future.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ethel D Weld, MD Po Box 64442, Baltimore, MD 21264-4442 Ph: (410) 328-2882 | Ethel D Weld, MD 22 S Greene St, Baltimore, MD 21201-1544 Ph: (410) 328-2882 |
News Archive
The Centers for Disease Control and Prevention on Monday awarded $10 million to five medical centers to develop and test new approaches to combating infections acquired in hospitals and other care settings.
While more American mothers are breastfeeding today, non-Hispanic Black/African American women are less likely to initiate and continue breastfeeding, primarily due to a lack of desire and lack of self-efficacy, according to research presented Monday, Oct. 4, at the American Academy of Pediatrics (AAP) National Conference and Exhibition in San Francisco.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
Researchers at the Intermountain Medical Center Heart Institute in Salt Lake City have identified a biological process that may help physicians predict when someone with heart disease is likely to have a heart attack in the near future.
› Verified 4 days ago
Allison Weaver, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe Street, Meyer 8-134, Baltimore, MD 21287 Phone: 410-614-4474 Fax: 410-367-2770 | |
Cheryl Myers Hepp, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2882 Fax: 410-328-7607 | |
Omid Sanaei, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2284 Fax: 410-554-2184 | |
Sumedha Nallamothu, M.B.B.S Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe Street, Meyer 8-134, Baltimore, MD 21287 Phone: 410-614-4474 Fax: 410-367-2770 | |
Dr. Nejat Ahmed Mohammed, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 3001 S Hanover St, Baltimore, MD 21225 Phone: 410-350-3200 | |
Mahyar Toofantabrizi, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9000 Franklin Square Dr, Baltimore, MD 21237 Phone: 443-777-7000 | |
Lee-ann Marie Wagner, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2882 Fax: 410-328-7607 |